On Friday, September 7, 2025 the U.S. FDA approved Takeda’s supplemental Biologics License Application (sBLA) for VONVENDI to expand its indication for routine prophylaxis to reduce the frequency of bleeding episodes in adults with von Willebrand Disease (VWD), including those with Type 1 and 2 disease, and on-demand and perioperative management of bleeding in pediatric patients with VWD.
To learn more and read the press release, please visit Takeda.com.
English 
Español de Puerto Rico